Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of LivaNova PLC (NASDAQ:LIVN) by 18.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 12,929 shares of the company’s stock after purchasing an additional 2,014 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in LivaNova were worth $709,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets lifted its position in LivaNova by 98.3% during the 4th quarter. BNP Paribas Financial Markets now owns 22,338 shares of the company’s stock valued at $1,156,000 after acquiring an additional 11,075 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of LivaNova by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock worth $64,262,000 after purchasing an additional 74,067 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of LivaNova by 2.4% in the 4th quarter. Principal Financial Group Inc. now owns 225,385 shares of the company’s stock worth $11,661,000 after buying an additional 5,329 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of LivaNova by 34.6% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock worth $286,000 after buying an additional 1,418 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its stake in LivaNova by 183.7% during the fourth quarter. Panagora Asset Management Inc. now owns 157,899 shares of the company’s stock valued at $8,170,000 after buying an additional 102,235 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LIVN. Stifel Nicolaus increased their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Robert W. Baird reissued a “neutral” rating and set a $55.00 price objective on shares of LivaNova in a research report on Wednesday, August 28th. Finally, Needham & Company LLC raised their price objective on shares of LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $65.83.

LivaNova Price Performance

NASDAQ LIVN opened at $49.08 on Thursday. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The stock has a 50-day moving average of $49.75 and a 200 day moving average of $53.88. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -81.80 and a beta of 1.00.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.